Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.67 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.67 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.67 |
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 0.64 |
| ▸ | HTR1B known ✓ | P28222 | 4/20 | 0.64 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.64 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.64 |
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.64 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.64 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.64 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.64 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.64 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.64 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.64 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.64 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.64 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.64 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.64 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL686594 | 1.00 | HTR2A (0.97) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| SCHEMBL30724496 | 0.98 | HTR2A (1.00) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| SCHEMBL626030 | 0.98 | HTR2A (1.00) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| Methane SCHEMBL26617454 | 0.97 | HTR2A (0.97) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| Cyanide SCHEMBL28680847 | 0.94 | HTR2A (0.91) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| Oxalic Acid SCHEMBL30724502 | 0.90 | HTR2A (0.83) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| Oxalic Acid SCHEMBL27132838 | 0.90 | HTR2A (0.83) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| SCHEMBL892989 | 0.89 | HTR2A (0.82) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| Oxalic Acid SCHEMBL27125982 | 0.88 | HTR2A (0.81) | HTR2ATRPM8HTR1AHTR2CHTR2B | |
| Oxalic Acid SCHEMBL30724503 | 0.88 | HTR2A (0.81) | HTR2ATRPM8HTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | CAAMTECH, INC. | 2024-08-22 | — | — | US | claimed |
| EP-4731623-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC Therapeutics, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025006078-A1 | CARBOLINE COMPOUNDS AND USE THEREOF | PTC THERAPEUTICS, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | CAAMTECH, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-3190109-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-11-10 | — | — | US | disclosed |
| US-9434722-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140066457-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2014-03-06 | — | — | US | disclosed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-2440550-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | HTR2A 106/4885HTR1A 122/4885HTR2C 253/4885 |
| US-20140066457-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | HTR2A 112/4885HTR1A 129/4885HTR2C 272/4885 |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | HTR2A 112/4885HTR1A 129/4885HTR2C 272/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | HTR2A 106/4885HTR1A 122/4885HTR2C 253/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | HTR2A 112/4885HTR1A 129/4885HTR2C 272/4885 |
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | SLC6A4, HTR2A, CMA1 | HTR2A 2/4885HTR1A 11/4885HTR2C 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.